GlassScriptPhysician profile
Gary Stephen Crawford
NPI 1619963121
$7,697.59
in general payments reported to CMS, 2019-2025
40 companies · $359 in 2025
The $359 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,080 · 2020: $1,108 · 2021: $1,071 · 2022: $1,206 · 2023: $1,186 · 2024: $688 · 2025: $359.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,233.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,232.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $964.70 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $832.13 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Lilly USA, LLC | $659.13 | 2019-2025 | Jardiance, Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $514.60 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Pfizer INC. | $477.80 | 2019-2025 | |
| Amgen INC. | $391.15 | 2019-2025 | Repatha, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $363.52 | 2019-2022 | |
| Eisai INC. | $334.74 | 2019-2021 | |
| Abbvie INC. | $293.71 | 2020-2025 | Ubrelvy, Qulipta |
| Takeda Pharmaceuticals U.S.A., INC. | $292.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $279.99 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $232.38 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $231.42 | 2019-2023 | |
| E.R. Squibb & Sons, L.L.C. | $216.02 | 2019-2024 | Eliquis, Camzyos |
| Amarin Pharma, INC. | $191.87 | 2019-2022 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Crawford listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.